VRM
PVLA

Vectors Research Management’s Palvella Therapeutics PVLA Stock Holding History

Vectors Research Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25
Closed -$8K – 524
2021
Q2 		$8K Buy
+25
New +$5.48K ﹤0.01% 412

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vectors Research Management's PVLA Position: Q3 2021 in Review

Vectors Research Management sold out of Palvella Therapeutics (PVLA) in Q3 2021, closing a stake of 25 shares — an estimated $8K sold.

Vectors Research Management first reported a position in PVLA in Q2 2021 and held it in 1 quarter. The position peaked at $8K in Q2 2021. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

  • Vectors Research Management reported no remaining Palvella Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vectors Research Management sold 25 Palvella Therapeutics shares in Q3 2021, an estimated $8K.
  • Vectors Research Management first reported a position in Palvella Therapeutics in Q2 2021 and held it in 1 quarter.
  • Vectors Research Management's Palvella Therapeutics position peaked at $8K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on Vectors Research Management's 13F filing for Q3 2021, filed 12 Nov 2021.